Literature DB >> 21919996

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.

C Torti1, M Prosperi, D Motta, S Digiambenedetto, F Maggiolo, G Paraninfo, D Ripamonti, G Cologni, M Fabbiani, S L Caputo, L Sighinolfi, N Ladisa, I El-Hamad, E Quiros-Roldan, I Frank.   

Abstract

We evaluated factors associated with normalization of the absolute CD4+ T-cell counts, per cent CD4+ T cells and CD4+/CD8+ T-cell ratio. A multicentre observational study was carried out in patients with sustained HIV-RNA <50 copies/mL. Outcomes were: CD4-count >500/mm(3) and multiple T-cell marker recovery (MTMR), defined as CD4+ T cells >500/mm(3) plus%CD4 T cells >29%plus CD4+/CD8+ T-cell ratio >1. Kaplan-Meier survival analysis and Cox regression analyses to predict odds for achieving outcomes were performed. Three hundred and fifty-two patients were included and followed-up for a median of 4.1 (IQR 2.1-5.9) years, 270 (76.7%) achieving a CD4+ T-cell count >500 cells/mm(3) and 197 (56%) achieving MTMR. Using three separate Cox models for both outcomes we demonstrated that independent predictors were: both absolute CD4+ and CD8+ T-cell counts, %CD4+ T cells, a higher CD4+/CD8+ T-cell ratio, and age. A likelihood-ratio test showed significant improvements in fitness for the prediction of either CD4+ >500/mm(3) or MTMR by multivariable analysis when the other immune markers at baseline, besides the absolute CD4+ count alone, were considered. In addition to baseline absolute CD4+ T-cell counts, pretreatment %CD4+ T cells and the CD4+/CD8+ T-cell ratio influence recovery of T-cell markers, and their consideration should influence the decision to start antiretroviral therapy. However, owing to the small sample size, further studies are needed to confirm these results in relation to clinical endpoints.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21919996     DOI: 10.1111/j.1469-0691.2011.03650.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  35 in total

1.  Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Authors:  V Sanchez-Merino; A Fabra-Garcia; N Gonzalez; D Nicolas; A Merino-Mansilla; C Manzardo; J Ambrosioni; A Schultz; A Meyerhans; J R Mascola; J M Gatell; J Alcami; J M Miro; E Yuste
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

2.  Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010.

Authors:  J R Koethe; C A Jenkins; B Lau; B E Shepherd; M J Silverberg; T T Brown; A J Blashill; A Anema; A Willig; S Stinnette; S Napravnik; J Gill; H M Crane; T R Sterling
Journal:  HIV Med       Date:  2015-05-11       Impact factor: 3.180

3.  CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy.

Authors:  Kathy Petoumenos; Jun Yong Choi; Jennifer Hoy; Sasisopin Kiertiburanakul; Oon Tek Ng; Mark Boyd; Reena Rajasuriar; Matthew Law
Journal:  Antivir Ther       Date:  2017

4.  Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.

Authors:  Jason F Okulicz; Tuan D Le; Brian K Agan; Jose F Camargo; Michael L Landrum; Edwina Wright; Matthew J Dolan; Anuradha Ganesan; Tomas M Ferguson; Davey M Smith; Douglas D Richman; Susan J Little; Robert A Clark; Weijing He; Sunil K Ahuja
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

5.  HIV infection and microbial diversity in saliva.

Authors:  Yihong Li; Deepak Saxena; Zhou Chen; Gaoxia Liu; Willam R Abrams; Joan A Phelan; Robert G Norman; Gene S Fisch; Patricia M Corby; Floyd Dewhirst; Bruce J Paster; Alexis S Kokaras; Daniel Malamud
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

6.  Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; Oksana Zakharova; JoAnn Kuruc; Cynthia Gay; Charles B Hicks; Kara S Mcgee; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

7.  Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Authors:  Eugènia Negredo; Marta Massanella; Maria C Puertas; Maria J Buzón; Jordi Puig; Núria Pérez-Alvárez; Josué Pérez-Santiago; Anna Bonjoch; José Moltó; Antoni Jou; Patricia Echeverría; Josep M Llibre; Javier Martínez-Picado; Bonaventura Clotet; Julià Blanco
Journal:  J Antimicrob Chemother       Date:  2013-05-14       Impact factor: 5.790

8.  Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment.

Authors:  John R Koethe; Cathy A Jenkins; Bryan Lau; Bryan E Shepherd; William Wester; Peter F Rebeiro; Michael J Silverberg; Jennifer E Thorne; John Gill; Angel M Mayor; Amanda Willig; Ronald Bosch; Michael A Horberg; Amy C Justice; Timothy R Sterling; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2016-10-01       Impact factor: 3.731

9.  Polymorphisms in the CD14 and TLR4 genes independently predict CD4+ T-cell recovery in HIV-infected individuals on antiretroviral therapy.

Authors:  Yean K Yong; Esaki M Shankar; Ajantha Solomon; Tim Spelman; Christopher K Fairley; Julian H Elliott; Jennifer Hoy; Paul U Cameron; Adeeba Kamarulzaman; Sharon R Lewin
Journal:  AIDS       Date:  2016-09-10       Impact factor: 4.177

10.  Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort.

Authors:  Sabina Herrera; Borja M Fernandez-Felix; Peter W Hunt; Steven G Deeks; Talía Sainz; Sonya L Heath; Chad J Achenbach; Benigno Rodríguez; Christopher Mathews; Katerina Christopoulos; Kenneth Mayer; Sonia Napravnik; Santiago Moreno; Sergio Serrano-Villar
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.